Form 4: Arcus Biosciences COO Sells Shares After Option Exercise

Arcus Biosciences' Chief Operating Officer, Jennifer Jarrett, sold 50,291 shares of common stock on November 7, 2025, following the exercise of stock options, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Jennifer Jarrett, Chief Operating Officer of Arcus Biosciences, Inc. (RCUS), executed a transaction on November 7, 2025.
• She acquired 50,291 shares of common stock by exercising stock options at a price of $1.2276 per share.
• Concurrently, she sold 50,291 shares of common stock at a weighted average price of $18.9709 per share, with individual sales ranging from $18.59 to $19.42.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
• Following these transactions, Jarrett beneficially owns 214,232 shares of common stock and 80,583 stock options.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale under a pre-arranged plan, which is common for executive compensation. It doesn't inherently signal strong positive or negative sentiment about the company's future, though any insider selling can be viewed with slight caution.

Positives

• The exercise of options indicates the options were 'in the money,' meaning the market price was significantly higher than the exercise price, allowing the COO to realize a substantial gain.
• The transaction was executed under a Rule 10b5-1 trading plan, which suggests a pre-planned sale not based on immediate, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a key executive in the company.
• The sale of all shares acquired through the option exercise indicates a cash-out rather than an increase in direct shareholding.

Future Outlook

NA

Industry Context

This is an insider transaction, which is common across all industries for executives managing their personal portfolios and compensation. It does not directly reflect broader industry trends.

Comparison to Industry Standards

• Insider transactions like option exercises and subsequent sales are standard compensation practices for executives in publicly traded companies, particularly in the biotechnology sector.
• The use of a 10b5-1 plan is also a common practice to manage such transactions in compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: The sale slightly increases the float of shares available in the market and reduces the direct ownership stake of a key executive. While the sale is under a 10b5-1 plan, some investors might interpret insider selling as a lack of confidence, though this is not necessarily the case for routine compensation-related sales.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Operating Officer exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and do not typically indicate a change in the company's fundamental outlook or performance. Therefore, based solely on this filing, there is no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation. Investors should look to broader company performance, financial reports, and strategic announcements for investment decisions.

Keywords

Arcus Biosciences, RCUS, Jennifer Jarrett, Chief Operating Officer, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Beneficial Ownership